Dierickx Lawrence, Nuclear Oncology, Coordinator at Institut Universitaire Cancer Toulouse Oncopole, shared a post on LinkedIn:
“A tremendous amount of work went into this international multicentre study, and I am very happy to have contributed to this important collaborative effort.
The study demonstrates a significant improvement in progression-free survival with 177Lu-edotreotide compared with everolimus in patients with gastroenteropancreatic neuroendocrine tumours.
Congratulations to all the investigators, study teams, and patients who made these results possible. Special congratulations to Thomas Walter and Jaume Capdevila for their outstanding leadership and dedication in bringing this ambitious study to fruition.”
Title: [177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial
Authors: Thomas Walter, Henning Jann, Catherine Ansquer, Emmanuel Deshayes, Rocio Garcia-Carbonero, Alexandre Teulé, Richard P Baum, Hein J Verberne, Jarosław B Ćwikła, Rajaventhan Srirajaskanthan, Louis de Mestier, Chiara M Grana, Andreas Buck, Dieter Hörsch, Marianne Pavel, Lawrence O Dierickx, Michael Michael, Jonathan Strosberg, Attila Kollár, Paula Jimenez-Fonseca, Anja Rinke, Maribel del Olmo-García, Anthime Flaus, Jorge Hernando, Andreas Kluge, Monika Breuninger, Serhii Melnyk, Konstantin Zhernosekov, Jaume Capdevila for the COMPETE Investigator Team
Other articles about Everolimus on OncoDaily.